$40.50
1.29%
Nasdaq, Sep 18, 12:55 pm EDT. Market open.
ISIN
BMG762791017
Symbol
ROIV

Roivant Sciences Target price 2026 - Analyst rating & recommendation

Roivant Sciences Classifications & Recommendation

Buy
89%
Hold
11%

Roivant Sciences Price Target

Target Price $41.82
Price $39.98
Potential
Number of Estimates 14
14 Analysts have issued a price target Roivant Sciences 2027 . The average Roivant Sciences target price is $41.82. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 19 analysts: 17 Analysts recommend Roivant Sciences to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Roivant Sciences stock has an average upside potential 2027 of . Most analysts recommend the Roivant Sciences stock at Purchase.

Sales and Margin forecast 2027, 2028 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Revenue Million $ 8.26 52.10
71.57% 530.74%
EBITDA Margin -14,841.40% -2,686.21%
292.09% 81.90%
Net Margin -3,629.18% -2,061.20%
513.02% 43.20%

14 Analysts have issued a sales forecast Roivant Sciences 2027 . The average Roivant Sciences sales estimate is

$52.1m
unlock
. This is
591.89% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$136m 1,702.12%
unlock
, the lowest is
$13.6m 80.98%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2026 $8.3m 71.57%
2027
$52.1m 530.74%
unlock
2028
$367m 605.00%
unlock
2029
$1.5b 320.64%
unlock
2030
$3.2b 109.06%
unlock
2031
$4.8b 48.30%
unlock
2032
$6.7b 40.10%
unlock
2033
$8.4b 24.72%
unlock

6 Analysts have issued an Roivant Sciences EBITDA forecast 2027. The average Roivant Sciences EBITDA estimate is

$-1.4b
unlock
. This is
10.60% lower
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-1.3b 0.28%
unlock
, the lowest is
$-1.5b 15.55%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2026 $-1.2b 11.48%
2027
$-1.4b 14.16%
unlock
2028
$-1.3b 8.93%
unlock
2029
$-837m 34.34%
unlock

EBITDA Margin

2026 -14,841.40% 292.09%
2027
-2,686.21% 81.90%
unlock
2028
-347.00% 87.08%
unlock
2029
-54.17% 84.39%
unlock

14 Roivant Sciences Analysts have issued a net profit forecast 2027. The average Roivant Sciences net profit estimate is

$-1.1b
unlock
. This is
303.33% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-820m 207.80%
unlock
, the lowest is
$-1.4b 421.62%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2026 $-300m 74.31%
2027
$-1.1b 258.23%
unlock
2028
$-995m 7.30%
unlock
2029
$-272m 72.68%
unlock
2030
$980m 460.43%
unlock
2031
$2.0b 107.52%
unlock
2032
$3.3b 62.32%
unlock
2033
$4.5b 35.27%
unlock

Net Margin

2026 -3,629.18% 513.02%
2027
-2,061.20% 43.20%
unlock
2028
-271.03% 86.85%
unlock
2029
-17.61% 93.50%
unlock
2030
30.35% 272.35%
unlock
2031
42.47% 39.93%
unlock
2032
49.21% 15.87%
unlock
2033
53.37% 8.45%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Earnings Per Share $ -0.43 -1.49
86.96% 246.51%
P/E negative
EV/Sales 480.55

14 Analysts have issued a Roivant Sciences forecast for earnings per share. The average Roivant Sciences EPS is

$-1.49
unlock
. This is
282.05% lower
unlock
than earnings per share in the financial year 2026. The highest EPS forecast is
$-1.13 189.74%
unlock
, the lowest is
$-1.92 392.31%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2026 $-0.43 86.96%
2027
$-1.49 246.51%
unlock
2028
$-1.38 7.38%
unlock
2029
$-0.38 72.46%
unlock
2030
$1.36 457.89%
unlock
2031
$2.82 107.35%
unlock
2032
$4.57 62.06%
unlock
2033
$6.18 35.23%
unlock

P/E ratio

Current -102.51 424.21%
2027
-26.91 73.75%
unlock
2028
-29.02 7.84%
unlock
2029
-106.22 266.02%
unlock
2030
29.47 127.74%
unlock
2031
14.20 51.82%
unlock
2032
8.75 38.38%
unlock
2033
6.47 26.06%
unlock

Based on analysts' sales estimates for 2027, the Roivant Sciences stock is valued at an EV/Sales of

480.55
unlock
and an P/S ratio of
554.30
unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3,324.89 1,410.97%
2027
480.55 85.55%
unlock
2028
68.16 85.82%
unlock
2029
16.20 76.23%
unlock
2030
7.75 52.17%
unlock
2031
5.23 32.57%
unlock
2032
3.73 28.63%
unlock
2033
2.99 19.82%
unlock

P/S ratio

Current 3,835.12 826.57%
2027
554.30 85.55%
unlock
2028
78.62 85.82%
unlock
2029
18.69 76.23%
unlock
2030
8.94 52.17%
unlock
2031
6.03 32.57%
unlock
2032
4.30 28.62%
unlock
2033
3.45 19.82%
unlock

Current Roivant Sciences Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
TD Cowen
Locked
Locked
Locked Sep 09 2026
Guggenheim
Locked
Locked
Locked Sep 09 2026
Jefferies
Locked
Locked
Locked Sep 08 2026
HC Wainwright & Co.
Locked
Locked
Locked Sep 08 2026
HC Wainwright & Co.
Locked
Locked
Locked Aug 28 2026
Citigroup
Locked
Locked
Locked Aug 10 2026
Guggenheim
Locked
Locked
Locked Aug 07 2026
Analyst Rating Date
Locked
TD Cowen:
Locked
Locked
Sep 09 2026
Locked
Guggenheim:
Locked
Locked
Sep 09 2026
Locked
Jefferies:
Locked
Locked
Sep 08 2026
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 08 2026
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 28 2026
Locked
Citigroup:
Locked
Locked
Aug 10 2026
Locked
Guggenheim:
Locked
Locked
Aug 07 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today